Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Zevra Therapeutics Inc | 78 |
| 2 | Takeda Pharmaceutical Co Ltd | 40 |
| 3 | Johnson and Johnson | 38 |
| 4 | BASF SE | 37 |
| 5 | Roche Holding AG | 34 |
| 6 | Sanofi SA | 28 |
| 7 | Novartis AG | 22 |
| 8 | Shionogi and Co Ltd | 22 |
| 9 | Cleveland Clinic Foundation | 21 |
| 10 | Bristol Myers Squibb Co | 20 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 617 |
| 2 | C07D | Heterocyclic compounds | 612 |
| 3 | A61K | Medicinal preparations | 437 |
| 4 | C07C | Acyclic and carbocyclic compounds | 277 |
| 5 | C07F | Organometallic compounds | 159 |
| 6 | Y02A | Climate change adaptation | 71 |
| 7 | C07K | Peptides | 66 |
| 8 | C07B | General methods of organic chemistry | 58 |
| 9 | B01J | Chemical/physical processes (e.g. catalysts) | 50 |
| 10 | C08F | Polymers from C=C unsaturated bonds | 47 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Src kinase inhibitor compounds | 2002 | Merck and Co Inc | 230 |
| METHOD FOR TREATING DRUG-RESISTANT BACTERIAL AND OTHER INFECTIONS WITH CLIOQUINOL, PHANQUINONE, AND RELATED COMPOUNDS | 2009 | 110 | |
| BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | 2016 | Novartis AG | 64 |
| TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | 2009 | Bristol Myers Squibb Co | 90 |
| GLYCAN COMPOSITIONS AND USES THEREOF | 2017 | Kaleido Biosciences Inc | 46 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2019 | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Gustavo Portalone | Sapienza University of Rome | 4 |
| 2 | Blanca Rivero-Cruz | Universidad Nacional Autónoma de México | 2 |
| 3 | Andrea Scozzafava | University of Florence | 2 |
| 4 | Claudiu T. Supuran | University of Florence | 2 |
| 5 | Rachel Mata | Universidad Nacional Autónoma de México | 2 |
| 6 | Carlos M. Cerda‐García‐Rojas | Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional | 2 |
| 7 | Lei Jiao | Second Military Medical University | 1 |
| 8 | Jean Claude Fournier | Centre de Microbiologie du Sol et de l'Environnement | 1 |
| 9 | Catherine Z. Chen | National Institutes of Health | 1 |
| 10 | Alfonso Maresca | University of Florence | 1 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Synthesis of Aryl Ketones by Palladium(II)‐Catalyzed Decarboxylative Addition of Benzoic Acids to Nitriles | 2010 | 122 | Catalytic C–H Functionalization Methods |
| Antioxidative Phenols and Phenolic Glycosides from Curculigo orchioides | 2005 | 99 | Phytochemicals and Antioxidant Activities |
| Antiosteoporotic activity of phenolic compounds from Curculigo orchioides | 2009 | 90 | Bone Metabolism and Diseases |
| Methoxy-Directed Aryl-to-Aryl 1,3-Rhodium Migration | 2013 | 52 | Catalytic C–H Functionalization Methods |
| Crystallographic Fragment‐Based Drug Discovery: Use of a Brominated Fragment Library Targeting HIV Protease | 2013 | 43 | Protein Structure and Dynamics |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of 2,6-dimethoxybenzoic acid?
Which organizations hold the most patents related to 2,6-dimethoxybenzoic acid?
How has patent activity for 2,6-dimethoxybenzoic acid changed over time?
What are the primary intellectual property classification areas for patents involving this compound?
Who are the most prolific academic authors publishing on 2,6-dimethoxybenzoic acid?